Nov. 10 Lead Plaintiff Deadline Set in Lantheus Pylarify Securities Suits

Overview

• Lawsuits and investigations announced by Kessler Topaz, Bernstein Liebhard, Faruqi & Faruqi, Pomerantz, Howard G. Smith, and Robbins Geller focus on Lantheus’s radiopharmaceutical product Pylarify.
• The putative class covers purchasers of Lantheus securities from February 26, 2025 through August 5, 2025, with motions for lead plaintiff due November 10, 2025.
• Complaints allege the company misled investors about Pylarify’s competitive position and pricing dynamics, including that an early‑2025 price increase exposed the product to competitive price erosion.
• Plaintiffs point to two market shocks following company updates: a roughly 23% share-price drop on May 7, 2025 and about a 28.8% single-day decline on August 6, 2025 after reduced Pylarify growth, including an 8.3% year-over-year sales fall.
• Robbins Geller notes the case is filed in the Southern District of New York as Margolis v. Lantheus Holdings, and firms emphasize that investors can seek lead-plaintiff status without affecting potential recovery, with outreach also directed to whistleblowers.